Neovastat

Neovastat (Æ-941) is a multifunctional antiangiogenic agent derived from shark cartilage. It acts as an inhibitor of angiogenesis and metalloproteases. Its mechanism of action includes preventing the binding of vascular endothelial growth factor (VEGF) to its receptors and inhibiting the gelatinolytic and elastinolytic activities of matrix metalloproteinases MMP-2, MMP-9, and MMP-12. These actions disrupt tumor neovascularization and extracellular matrix degradation—key processes in tumor growth and metastasis. Additionally, Neovastat induces apoptosis in target cells. It was developed primarily for cancer indications such as renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), multiple myeloma, prostate cancer, breast cancer, age-related macular degeneration (AMD), osteoarthritis, rheumatoid arthritis, psoriasis/psoriatic disorders. Despite reaching phase III clinical trials for several indications—including NSCLC—development has been discontinued for all known uses[2][3][4][5][6][7].

Brand names

NeovastatArthrovasNeoretnaPsovascar

Other names

Shark cartilage extract AE-941